$IVA

Inventiva (Euronext: IVA, NASDAQ: IVA) announced it will present three scientific abstracts at AASLD The Liver Meeting 2026. The abstracts highlight preclinical and Phase 2b data on lanifibranor, its lead drug candidate for treating MASH. Lanifibranor is currently in Phase 3 trials, with topline results expected in Q4 2026. The company believes lanifibranor's balanced pan-PPAR activation addresses multiple drivers of MASH pathophysiology.

Inventiva S.A. (IVA) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 ​ ​ Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update ● Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 ● Cash runway guidance remains unchanged from July 30, 2026 2

Inventiva (IVA) reported a narrower H1 2026 net loss of EUR69.47M, down from EUR175.88M in H1 2025. Revenue fell to EUR0.02M, while R&D expenses rose to EUR46.24M. The company expects to fund operations through Q2 2027. NATiV3 trial results for lanifibranor are anticipated in Q4 2026, with potential U.S. launch in 2028. IVA shares closed at $3.37, down 3.26% in premarket.

Inventiva SA reported a net loss of €69.5M for the period, an improvement from the prior year, with no revenue. Cash reserves stood at €233.9M. The NATIV3 Phase 3 trial completed patient visits, with results expected in Q4 2026 and a potential regulatory submission in H1 2027.

Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.

Inventiva (IVA) will present five abstracts at the 12th Paris MASH Meeting, showcasing Phase 1 and 2 clinical and preclinical data for lanifibranor, its lead drug candidate. The data suggests improvements in metabolic profiles and cardiovascular risk factors in MASH patients, with or without type 2 diabetes. Lanifibranor is currently in a Phase 3 trial, with topline results expected in Q4 2026.

Inventiva (Euronext: IVA, NASDAQ: IVA) appointed Chris Benecchi as Chief Operating Officer to lead operational readiness ahead of its Phase 3 trial results for lanifibranor, a potential MASH treatment, expected in Q4 2026. Benecchi brings extensive biopharmaceutical experience and will prepare the company for a potential 2028 U.S. launch, subject to regulatory approval.

Inventiva (Euronext Paris and Nasdaq: IVA) reported preliminary 1H 2026 results. Cash and cash equivalents were €166.1 million at June 30, 2026, versus €99.3 million at Dec. 31, 2025. Net cash used in operating activities was (€48.7) million. R&D expenses were (€50.1) million. No revenues were recorded. The company expects funding into Q2 2027, or Q1 2028 with potential tranches.

Inventiva S.A. (NASDAQ:IVA) said July 9 it completed the final step of its June 2, 2026 EIB warrant restructuring. The company issued about 15.7 million new warrants to the European Investment Bank and canceled remaining legacy EIB warrants not repurchased. Inventiva said the change removes anti-dilution provisions and improves capital structure as it advances lanifibranor for MASH.

Inventiva (Euronext Paris and Nasdaq: IVA) said it completed its EIB warrant restructuring, issuing 15.7 million new EIB warrants to the European Investment Bank and cancelling remaining legacy EIB warrants not repurchased. New warrants are priced and exercisable at €0.01, expire Jan. 4, 2036, and would equal about 6.5% of current share capital if exercised.